Daily Archives: 20/01/2011

Patents & IP news: 20/01/2011

1) Biocon says revenue from Pfizer deal to begin in fiscal 2012 (Bloomberg); Pfizer and Biocon recently entered into agreement. Under this agreement, Pfizer will have exclusive rights to commercialise Biocon’s drugs recombinant human insulin, Glargine, Aspart and Lispro globally with certain … Continue reading

Posted in Daily interesting IP news | 2 Comments

Novo nordisk – repaglinide combination patent invalid

Yesterday, The district court of Michigan ruled that OB listed 6,677,358 (exp: Jun 12, 2018) patent is invalid and unenforceable. Press release “… The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 … Continue reading

Posted in Daily interesting IP news, Patent case | Tagged , , , , | Leave a comment